{
 "cells": [
  {
   "cell_type": "code",
   "execution_count": 1,
   "id": "8fc8fb81",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>Id</th>\n",
       "      <th>Name</th>\n",
       "      <th>Applications__c</th>\n",
       "      <th>Brand_Name__c</th>\n",
       "      <th>Chemical_Name__c</th>\n",
       "      <th>Applicants__c</th>\n",
       "      <th>Funding_requested_for__c</th>\n",
       "      <th>Stage__c</th>\n",
       "      <th>Pharmaceutical__c</th>\n",
       "      <th>Community_URL__c</th>\n",
       "      <th>Therapeutic_group__c</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>a0ROZ000009J5Ev2AK</td>\n",
       "      <td>15-valent pneumococcal conjugate vaccine (PCV15)</td>\n",
       "      <td>A-04423</td>\n",
       "      <td>VAXNEUVANCE.</td>\n",
       "      <td>15-valent pneumococcal conjugate vaccine (PCV15)</td>\n",
       "      <td>MERCK SHARP &amp; DOHME (NEW ZEALAND) LIMITED</td>\n",
       "      <td>Prevention of invasive pneumococcal disease</td>\n",
       "      <td>Decision</td>\n",
       "      <td>15-valent pneumococcal conjugate vaccine (PCV1...</td>\n",
       "      <td>https://connect.pharmac.govt.nz/apptracker/s/a...</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>a0ROZ000004CX2l2AG</td>\n",
       "      <td>Adjuvanted inactivated quadrivalent influenza ...</td>\n",
       "      <td>A-03341</td>\n",
       "      <td>FLUAD® QUAD</td>\n",
       "      <td>Adjuvanted inactivated quadrivalent influenza ...</td>\n",
       "      <td>Seqirus</td>\n",
       "      <td>influenza vaccination for people aged 65 years...</td>\n",
       "      <td>Decision</td>\n",
       "      <td>Adjuvanted inactivated quadrivalent influenza ...</td>\n",
       "      <td>https://connect.pharmac.govt.nz/apptracker/s/a...</td>\n",
       "      <td>National Immunisation Schedule</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>a0ROZ00000Cn1xE2AR</td>\n",
       "      <td>Adjuvanted inactivated trivalent influenza vac...</td>\n",
       "      <td>A-00724</td>\n",
       "      <td>Fluad</td>\n",
       "      <td>Adjuvanted inactivated trivalent influenza vac...</td>\n",
       "      <td>Seqirus</td>\n",
       "      <td>Influenza vaccine for people 65 years of age a...</td>\n",
       "      <td>Options Compared</td>\n",
       "      <td>Adjuvanted inactivated trivalent influenza vac...</td>\n",
       "      <td>https://connect.pharmac.govt.nz/apptracker/s/a...</td>\n",
       "      <td>National Immunisation Schedule</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>a0R2P000000gVYDUA2</td>\n",
       "      <td>Bevacizumab and Human Papillomavirus (HPV) vac...</td>\n",
       "      <td>A-00655</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Bevacizumab and Human Papillomavirus (HPV) vac...</td>\n",
       "      <td>PHARMAC Initiated</td>\n",
       "      <td>Recurrent respiratory papillomatosis</td>\n",
       "      <td>Decision</td>\n",
       "      <td>Bevacizumab and Human Papillomavirus (HPV) vac...</td>\n",
       "      <td>https://connect.pharmac.govt.nz/apptracker/s/a...</td>\n",
       "      <td>Respiratory System and Allergies</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>a0R2P000000LmcWUAS</td>\n",
       "      <td>Diphtheria and tetanus vaccine</td>\n",
       "      <td>A-00221</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Diphtheria and tetanus vaccine</td>\n",
       "      <td>PHARMAC Initiated</td>\n",
       "      <td>Widening of access</td>\n",
       "      <td>Decision</td>\n",
       "      <td>Diphtheria and tetanus vaccine</td>\n",
       "      <td>https://connect.pharmac.govt.nz/apptracker/s/a...</td>\n",
       "      <td>National Immunisation Schedule</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>...</th>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2010</th>\n",
       "      <td>a0ROZ00000083aG2AQ</td>\n",
       "      <td>AEON Sodium Chloride 5 Percent</td>\n",
       "      <td>A-04432</td>\n",
       "      <td>AEON</td>\n",
       "      <td>AEON Sodium Chloride 5 Percent</td>\n",
       "      <td>MEDIX 21 LIMITED</td>\n",
       "      <td>Corneal oedema relief</td>\n",
       "      <td>Seeking Clinical Advice</td>\n",
       "      <td>AEON Sodium Chloride 5 Percent (AEON)</td>\n",
       "      <td>https://connect.pharmac.govt.nz/apptracker/s/a...</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2011</th>\n",
       "      <td>a0ROZ00000DqVYD2A3</td>\n",
       "      <td>Pegunigalsidase alfa-iwxj</td>\n",
       "      <td>A-05325</td>\n",
       "      <td>ELFABRIO</td>\n",
       "      <td>Pegunigalsidase alfa-iwxj</td>\n",
       "      <td>CHIESI NEW ZEALAND LIMITED</td>\n",
       "      <td>Fabry Disease</td>\n",
       "      <td>Options Compared</td>\n",
       "      <td>Pegunigalsidase alfa-iwxj (ELFABRIO)</td>\n",
       "      <td>https://connect.pharmac.govt.nz/apptracker/s/a...</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2012</th>\n",
       "      <td>a0ROZ000003nufF2AQ</td>\n",
       "      <td>Elemental Food (Elemental Gold)</td>\n",
       "      <td>A-04296</td>\n",
       "      <td>It is not a pharmaceutical. The brand name is ...</td>\n",
       "      <td>Elemental Food (Elemental Gold)</td>\n",
       "      <td>ENDOTHERAPEUTICS NZ LIMITED</td>\n",
       "      <td>Currently funded indications</td>\n",
       "      <td>Seeking Clinical Advice</td>\n",
       "      <td>Elemental Food (Elemental Gold) (It is not a p...</td>\n",
       "      <td>https://connect.pharmac.govt.nz/apptracker/s/a...</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2013</th>\n",
       "      <td>a0ROZ00000AQkoE2AT</td>\n",
       "      <td>SARS-CoV-2 rS (Omicron XBB.1.5)</td>\n",
       "      <td>A-04785</td>\n",
       "      <td>NUVAXOVID XBB.1.5</td>\n",
       "      <td>SARS-CoV-2 rS (Omicron XBB.1.5)</td>\n",
       "      <td>BIOCELECT NEW ZEALAND LIMITED</td>\n",
       "      <td>prevention of COVID-19</td>\n",
       "      <td>Options Compared</td>\n",
       "      <td>SARS-CoV-2 rS (Omicron XBB.1.5) (NUVAXOVID XBB...</td>\n",
       "      <td>https://connect.pharmac.govt.nz/apptracker/s/a...</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2014</th>\n",
       "      <td>a0ROZ0000070NGj2AM</td>\n",
       "      <td>Elasomeran, Elasomeran and Davesomeran, Anduso...</td>\n",
       "      <td>A-04863</td>\n",
       "      <td>SPIKEVAX</td>\n",
       "      <td>Elasomeran, Elasomeran and Davesomeran, Anduso...</td>\n",
       "      <td>Moderna Australia Pty Ltd</td>\n",
       "      <td>active immunisation to prevent coronavirus dis...</td>\n",
       "      <td>Under Assessment</td>\n",
       "      <td>Elasomeran, Elasomeran and Davesomeran, Anduso...</td>\n",
       "      <td>https://connect.pharmac.govt.nz/apptracker/s/a...</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>2015 rows × 11 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "                      Id                                               Name  \\\n",
       "0     a0ROZ000009J5Ev2AK   15-valent pneumococcal conjugate vaccine (PCV15)   \n",
       "1     a0ROZ000004CX2l2AG  Adjuvanted inactivated quadrivalent influenza ...   \n",
       "2     a0ROZ00000Cn1xE2AR  Adjuvanted inactivated trivalent influenza vac...   \n",
       "3     a0R2P000000gVYDUA2  Bevacizumab and Human Papillomavirus (HPV) vac...   \n",
       "4     a0R2P000000LmcWUAS                     Diphtheria and tetanus vaccine   \n",
       "...                  ...                                                ...   \n",
       "2010  a0ROZ00000083aG2AQ                     AEON Sodium Chloride 5 Percent   \n",
       "2011  a0ROZ00000DqVYD2A3                          Pegunigalsidase alfa-iwxj   \n",
       "2012  a0ROZ000003nufF2AQ                    Elemental Food (Elemental Gold)   \n",
       "2013  a0ROZ00000AQkoE2AT                    SARS-CoV-2 rS (Omicron XBB.1.5)   \n",
       "2014  a0ROZ0000070NGj2AM  Elasomeran, Elasomeran and Davesomeran, Anduso...   \n",
       "\n",
       "     Applications__c                                      Brand_Name__c  \\\n",
       "0            A-04423                                       VAXNEUVANCE.   \n",
       "1            A-03341                                        FLUAD® QUAD   \n",
       "2            A-00724                                              Fluad   \n",
       "3            A-00655                                                NaN   \n",
       "4            A-00221                                                NaN   \n",
       "...              ...                                                ...   \n",
       "2010         A-04432                                               AEON   \n",
       "2011         A-05325                                           ELFABRIO   \n",
       "2012         A-04296  It is not a pharmaceutical. The brand name is ...   \n",
       "2013         A-04785                                  NUVAXOVID XBB.1.5   \n",
       "2014         A-04863                                           SPIKEVAX   \n",
       "\n",
       "                                       Chemical_Name__c  \\\n",
       "0      15-valent pneumococcal conjugate vaccine (PCV15)   \n",
       "1     Adjuvanted inactivated quadrivalent influenza ...   \n",
       "2     Adjuvanted inactivated trivalent influenza vac...   \n",
       "3     Bevacizumab and Human Papillomavirus (HPV) vac...   \n",
       "4                        Diphtheria and tetanus vaccine   \n",
       "...                                                 ...   \n",
       "2010                     AEON Sodium Chloride 5 Percent   \n",
       "2011                          Pegunigalsidase alfa-iwxj   \n",
       "2012                    Elemental Food (Elemental Gold)   \n",
       "2013                    SARS-CoV-2 rS (Omicron XBB.1.5)   \n",
       "2014  Elasomeran, Elasomeran and Davesomeran, Anduso...   \n",
       "\n",
       "                                  Applicants__c  \\\n",
       "0     MERCK SHARP & DOHME (NEW ZEALAND) LIMITED   \n",
       "1                                       Seqirus   \n",
       "2                                       Seqirus   \n",
       "3                             PHARMAC Initiated   \n",
       "4                             PHARMAC Initiated   \n",
       "...                                         ...   \n",
       "2010                           MEDIX 21 LIMITED   \n",
       "2011                 CHIESI NEW ZEALAND LIMITED   \n",
       "2012                ENDOTHERAPEUTICS NZ LIMITED   \n",
       "2013              BIOCELECT NEW ZEALAND LIMITED   \n",
       "2014                  Moderna Australia Pty Ltd   \n",
       "\n",
       "                               Funding_requested_for__c  \\\n",
       "0           Prevention of invasive pneumococcal disease   \n",
       "1     influenza vaccination for people aged 65 years...   \n",
       "2     Influenza vaccine for people 65 years of age a...   \n",
       "3                  Recurrent respiratory papillomatosis   \n",
       "4                                    Widening of access   \n",
       "...                                                 ...   \n",
       "2010                              Corneal oedema relief   \n",
       "2011                                      Fabry Disease   \n",
       "2012                       Currently funded indications   \n",
       "2013                             prevention of COVID-19   \n",
       "2014  active immunisation to prevent coronavirus dis...   \n",
       "\n",
       "                     Stage__c  \\\n",
       "0                    Decision   \n",
       "1                    Decision   \n",
       "2            Options Compared   \n",
       "3                    Decision   \n",
       "4                    Decision   \n",
       "...                       ...   \n",
       "2010  Seeking Clinical Advice   \n",
       "2011         Options Compared   \n",
       "2012  Seeking Clinical Advice   \n",
       "2013         Options Compared   \n",
       "2014         Under Assessment   \n",
       "\n",
       "                                      Pharmaceutical__c  \\\n",
       "0     15-valent pneumococcal conjugate vaccine (PCV1...   \n",
       "1     Adjuvanted inactivated quadrivalent influenza ...   \n",
       "2     Adjuvanted inactivated trivalent influenza vac...   \n",
       "3     Bevacizumab and Human Papillomavirus (HPV) vac...   \n",
       "4                        Diphtheria and tetanus vaccine   \n",
       "...                                                 ...   \n",
       "2010              AEON Sodium Chloride 5 Percent (AEON)   \n",
       "2011               Pegunigalsidase alfa-iwxj (ELFABRIO)   \n",
       "2012  Elemental Food (Elemental Gold) (It is not a p...   \n",
       "2013  SARS-CoV-2 rS (Omicron XBB.1.5) (NUVAXOVID XBB...   \n",
       "2014  Elasomeran, Elasomeran and Davesomeran, Anduso...   \n",
       "\n",
       "                                       Community_URL__c  \\\n",
       "0     https://connect.pharmac.govt.nz/apptracker/s/a...   \n",
       "1     https://connect.pharmac.govt.nz/apptracker/s/a...   \n",
       "2     https://connect.pharmac.govt.nz/apptracker/s/a...   \n",
       "3     https://connect.pharmac.govt.nz/apptracker/s/a...   \n",
       "4     https://connect.pharmac.govt.nz/apptracker/s/a...   \n",
       "...                                                 ...   \n",
       "2010  https://connect.pharmac.govt.nz/apptracker/s/a...   \n",
       "2011  https://connect.pharmac.govt.nz/apptracker/s/a...   \n",
       "2012  https://connect.pharmac.govt.nz/apptracker/s/a...   \n",
       "2013  https://connect.pharmac.govt.nz/apptracker/s/a...   \n",
       "2014  https://connect.pharmac.govt.nz/apptracker/s/a...   \n",
       "\n",
       "                  Therapeutic_group__c  \n",
       "0                                  NaN  \n",
       "1       National Immunisation Schedule  \n",
       "2       National Immunisation Schedule  \n",
       "3     Respiratory System and Allergies  \n",
       "4       National Immunisation Schedule  \n",
       "...                                ...  \n",
       "2010                               NaN  \n",
       "2011                               NaN  \n",
       "2012                               NaN  \n",
       "2013                               NaN  \n",
       "2014                               NaN  \n",
       "\n",
       "[2015 rows x 11 columns]"
      ]
     },
     "execution_count": 1,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "import pandas as pd\n",
    "pd.set_option(\"display.max_columns\", None)\n",
    "from tqdm import tqdm\n",
    "from pprint import pprint\n",
    "tqdm.pandas()\n",
    "df = pd.read_csv(\"applications.csv\")\n",
    "df.Community_URL__c = \"https://connect.pharmac.govt.nz\" + df.Community_URL__c\n",
    "df"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 2,
   "id": "c92a1a50",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>text</th>\n",
       "      <th>position</th>\n",
       "      <th>name</th>\n",
       "      <th>last</th>\n",
       "      <th>events</th>\n",
       "      <th>dateString</th>\n",
       "      <th>collapsed</th>\n",
       "      <th>checked</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>&lt;p&gt;New funding applications are referred to on...</td>\n",
       "      <td>0</td>\n",
       "      <td>Application Received</td>\n",
       "      <td>False</td>\n",
       "      <td>[{'Summary': {'s': None, 'fs': None, 'change':...</td>\n",
       "      <td>Aug 2022</td>\n",
       "      <td>False</td>\n",
       "      <td>True</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>&lt;p&gt;Pharmac is identifying and gathering inform...</td>\n",
       "      <td>1</td>\n",
       "      <td>Seeking Clinical Advice</td>\n",
       "      <td>False</td>\n",
       "      <td>[{'Summary': {'s': None, 'fs': None, 'change':...</td>\n",
       "      <td>Sep 2022</td>\n",
       "      <td>False</td>\n",
       "      <td>True</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>&lt;p&gt;Following Clinical Advice, Pharmac staff co...</td>\n",
       "      <td>2</td>\n",
       "      <td>Under Assessment</td>\n",
       "      <td>False</td>\n",
       "      <td>[{'Summary': {'s': None, 'fs': None, 'change':...</td>\n",
       "      <td>Mar 2023</td>\n",
       "      <td>False</td>\n",
       "      <td>True</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>&lt;p&gt;Pharmac staff uses a prioritisation process...</td>\n",
       "      <td>3</td>\n",
       "      <td>Options Compared</td>\n",
       "      <td>False</td>\n",
       "      <td>[{'Summary': {'s': None, 'fs': None, 'change':...</td>\n",
       "      <td>Jun 2024</td>\n",
       "      <td>False</td>\n",
       "      <td>True</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>&lt;p&gt;Pharmac is consulting on a proposal to eith...</td>\n",
       "      <td>4</td>\n",
       "      <td>Under Consultation</td>\n",
       "      <td>False</td>\n",
       "      <td>[{'Summary': {'s': None, 'fs': None, 'change':...</td>\n",
       "      <td>Oct 2024</td>\n",
       "      <td>False</td>\n",
       "      <td>True</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>5</th>\n",
       "      <td>&lt;p&gt;Following the consultation process, Pharmac...</td>\n",
       "      <td>5</td>\n",
       "      <td>Reviewing Consultation Feedback</td>\n",
       "      <td>False</td>\n",
       "      <td>[{'Summary': {'s': None, 'fs': None, 'change':...</td>\n",
       "      <td>Nov 2024</td>\n",
       "      <td>False</td>\n",
       "      <td>True</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>6</th>\n",
       "      <td>&lt;p&gt;We refer to our decisions about whether and...</td>\n",
       "      <td>6</td>\n",
       "      <td>Decision</td>\n",
       "      <td>True</td>\n",
       "      <td>[{'Summary': {'s': None, 'fs': None, 'change':...</td>\n",
       "      <td>Jun 2025</td>\n",
       "      <td>False</td>\n",
       "      <td>True</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "                                                text  position  \\\n",
       "0  <p>New funding applications are referred to on...         0   \n",
       "1  <p>Pharmac is identifying and gathering inform...         1   \n",
       "2  <p>Following Clinical Advice, Pharmac staff co...         2   \n",
       "3  <p>Pharmac staff uses a prioritisation process...         3   \n",
       "4  <p>Pharmac is consulting on a proposal to eith...         4   \n",
       "5  <p>Following the consultation process, Pharmac...         5   \n",
       "6  <p>We refer to our decisions about whether and...         6   \n",
       "\n",
       "                              name   last  \\\n",
       "0             Application Received  False   \n",
       "1          Seeking Clinical Advice  False   \n",
       "2                 Under Assessment  False   \n",
       "3                 Options Compared  False   \n",
       "4               Under Consultation  False   \n",
       "5  Reviewing Consultation Feedback  False   \n",
       "6                         Decision   True   \n",
       "\n",
       "                                              events dateString  collapsed  \\\n",
       "0  [{'Summary': {'s': None, 'fs': None, 'change':...   Aug 2022      False   \n",
       "1  [{'Summary': {'s': None, 'fs': None, 'change':...   Sep 2022      False   \n",
       "2  [{'Summary': {'s': None, 'fs': None, 'change':...   Mar 2023      False   \n",
       "3  [{'Summary': {'s': None, 'fs': None, 'change':...   Jun 2024      False   \n",
       "4  [{'Summary': {'s': None, 'fs': None, 'change':...   Oct 2024      False   \n",
       "5  [{'Summary': {'s': None, 'fs': None, 'change':...   Nov 2024      False   \n",
       "6  [{'Summary': {'s': None, 'fs': None, 'change':...   Jun 2025      False   \n",
       "\n",
       "   checked  \n",
       "0     True  \n",
       "1     True  \n",
       "2     True  \n",
       "3     True  \n",
       "4     True  \n",
       "5     True  \n",
       "6     True  "
      ]
     },
     "execution_count": 2,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "events = pd.read_json(f\"applications/{df['Id'].iloc[0]}.json\")\n",
    "events"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 3,
   "id": "80763d50",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "[{'Event_Description': {'change': None,\n",
      "                        'fs': 'The funding application has been declined.',\n",
      "                        's': 'The funding application has been declined.'},\n",
      "  'Formatted_Date': {'change': None, 'fs': 'Jun 2025', 's': 'Jun 2025'},\n",
      "  'Links': {'change': None,\n",
      "            'fs': '<p><a '\n",
      "                  'href=\"https://www.pharmac.govt.nz/news-and-resources/consultations-and-decisions/2025-06-decision-to-decline-inactive-applications-for-the-funding-of-some-medicines\" '\n",
      "                  'target=\"_blank\">Notification of the decision</a></p>',\n",
      "            's': '<p><a '\n",
      "                 'href=\"https://www.pharmac.govt.nz/news-and-resources/consultations-and-decisions/2025-06-decision-to-decline-inactive-applications-for-the-funding-of-some-medicines\" '\n",
      "                 'target=\"_blank\">Notification of the decision</a></p>'},\n",
      "  'Outcome': {'change': None, 'fs': None, 's': None},\n",
      "  'PTAC_Comments': {'change': None, 'fs': None, 's': None},\n",
      "  'Published_Application': {'change': None, 'fs': None, 's': None},\n",
      "  'Published_Discussion': {'change': None, 'fs': None, 's': None},\n",
      "  'Published_Recommendation': {'change': None, 'fs': None, 's': None},\n",
      "  'Summary': {'change': None, 'fs': None, 's': None},\n",
      "  'change': None,\n",
      "  'e': {'Event_Date__c': '2025-06-17',\n",
      "        'Event_Description__c': 'The funding application has been declined.',\n",
      "        'Formatted_Date__c': 'Jun 2025',\n",
      "        'Id': 'a0POZ00000Mc77I2AR',\n",
      "        'Links__c': '<p><a '\n",
      "                    'href=\"https://www.pharmac.govt.nz/news-and-resources/consultations-and-decisions/2025-06-decision-to-decline-inactive-applications-for-the-funding-of-some-medicines\" '\n",
      "                    'target=\"_blank\">Notification of the decision</a></p>',\n",
      "        'Stage__c': 'Decision',\n",
      "        'Status_History__c': 'a13OZ00000OhRFMYA3',\n",
      "        'attributes': {'type': 'Application_Event__c',\n",
      "                       'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ00000Mc77I2AR'}}}]\n"
     ]
    }
   ],
   "source": [
    "pprint(events.events.iloc[-1])"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 4,
   "id": "02a4fb45",
   "metadata": {},
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      " 16%|█▌        | 313/2015 [00:01<00:08, 210.43it/s]"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "{'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Jul 2012', 'fs': 'Jul 2012', 'change': None}, 'Event_Description': {'s': None, 'fs': None, 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ000000vYNw2AM'}, 'Id': 'a0POZ000000vYNw2AM', 'Event_Date__c': '2012-07-01', 'Stage__c': 'Under Assessment', 'Formatted_Date__c': 'Jul 2012', 'Status_History__c': 'a132P000000Aq3yQAC'}, 'change': None}\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      " 42%|████▏     | 841/2015 [00:03<00:05, 212.71it/s]"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "{'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Dec', 'fs': 'Dec', 'change': None}, 'Event_Description': {'s': 'Public consultation for this application is now closed. Pharmac is reviewing consultation feedback.', 'fs': 'Public consultation for this application is now closed. Pharmac is reviewing consultation feedback.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0P2P000007JyAAUA0'}, 'Id': 'a0P2P000007JyAAUA0', 'Event_Description__c': 'Public consultation for this application is now closed. Pharmac is reviewing consultation feedback.', 'Stage__c': 'Reviewing Consultation Feedback', 'Formatted_Date__c': 'Dec', 'Status_History__c': 'a132P000000Clc2QAC'}, 'change': None}\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      " 55%|█████▌    | 1111/2015 [00:05<00:04, 222.15it/s]"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "{'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Aug 2022', 'fs': 'Aug 2022', 'change': None}, 'Event_Description': {'s': None, 'fs': None, 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ0000012oZf2AI'}, 'Id': 'a0POZ0000012oZf2AI', 'Event_Date__c': '2022-08-01', 'Stage__c': 'Seeking Clinical Advice', 'Formatted_Date__c': 'Aug 2022', 'Status_History__c': 'a132P000000DwrGQAS'}, 'change': None}\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      " 71%|███████   | 1432/2015 [00:06<00:02, 214.14it/s]"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "{'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': '<p>The Committee recommended the new formulation and device of adalimumab be listed on the Pharmaceutical Schedule if cost-neutral to the existing presentations of adalimumab, including the future costs of adalimumab with regards to patent extension and the introduction of biosimilar presentations.</p><p><br></p><p>The Committee took into account, where applicable, PHARMAC&#39;s relevant decision-making framework for these recommendations.</p>', 'fs': '<p>The Committee recommended the new formulation and device of adalimumab be listed on the Pharmaceutical Schedule if cost-neutral to the existing presentations of adalimumab, including the future costs of adalimumab with regards to patent extension and the introduction of biosimilar presentations.</p><p><br></p><p>The Committee took into account, where applicable, PHARMAC&#39;s relevant decision-making framework for these recommendations.</p>', 'change': None}, 'Published_Discussion': {'s': '<p>The Committee noted that adalimumab 10 mg, 20 mg and 40 mg subcutaneous presentations are currently listed on Pharmaceutical Schedule, subject to a Special Authority for a range of conditions. The Committee noted that some patients experience significant pain associated with the subcutaneous injection of adalimumab with the currently listed product, however these patients are receiving treatment for chronic conditions that are associated with ongoing pain and the benefit of treatment would usually outweigh the short-term injection related pain.</p><p><br></p><p>Members noted that adalimumab appears to be a more painful injection than etanercept, however only a small number of patients report that injection associated pain was the reason they switched to another injectable biologic (Navarro-Millán et al. PLoS ONE 2016;11(3):e0149781).</p><p><br></p><p>The Committee noted that the new presentation incorporates a two-fold change to the presentation of adalimumab (Humira) to create a citrate-free (CF) formulation, in order to reduce the injection volume, and changes the auto-injector pen device and needle size to aid administration. The current formulation and device could remain available until 30 June 2019 (the end of AbbVie’s current subsidy and delisting protection), although it would be the supplier’s preference to replace the current product sooner. Members noted there may be a potential stock risk in the future if New Zealand continues to list a product that is different to other countries and that PHARMAC staff would need to assess this risk.</p><p><br></p><p>The Committee noted the supplier submitted a new medicine application to Medsafe for the new 40 mg/0.4 ml formulation in March 2016 and registration is expected by May 2017. Members noted that registration of the 10 mg and 20 mg products is not expected until the end of 2018 and these strengths would continue to be available as pre-filled syringes only.</p><p><br></p><p>The Committee noted weak evidence that citrate buffers may be associated with increased pain on subcutaneous injection in comparison with alternatives such as histidine buffer or normal saline (Larsen et al. Basic &amp; Clinical Pharmacology &amp; Toxicology 2006; 98:218–21).\\xa0</p><p><br></p><p>Members noted increased injection volume is also associated with increased pain. However, Members considered both concentrations of adalimumab are in a relatively small volume (0.4 ml and 0.8ml). A study by Heise et al. (Diabetes, Obesity and Metabolism 2014;16:971–6) suggested that there may be little difference in pain on injection of either 0.4 or 0.8 ml volume. The Committee considered that it is unclear if a change in needle gauge from 29 to 27 would significantly affect pain on injection.</p><p><br></p><p>The Committee noted four studies provided in the application regarding pain on injection (M10-867, M11-964, M12-783, and M12-159). Two studies were relatively large Phase I trials (M10-867, M12-159) where pre-filled syringes were used to administer a single dose of one of the formulations to healthy subjects. Members noted the Visual Analogue Scale (VAS) scores immediately after injection were statistically significantly higher in the users of the original formulation. However, there was significant variation between subjects as indicated by a very large standard deviation in the numeric results. Pain had diminished significantly by 15 minutes in both treatment arms. Results for both Phase I studies were similar. </p><p><br></p><p>Members noted that two Phase II trials (M11-964 and M12-783) evaluated injection pain following use of a pre-filled syringe of either the current or high-concentration formulation, in treatment naïve and pain experienced patients who had received at least 6 consecutive adalimumab doses prior to screening. Members noted that a recently published paper (Nash et al. Rheumatol Ther August 2016, published online DOI 10.1007/s40744-016-0041-3) provides more detail regarding the VAS scores and shows a statistical difference in VAS immediately after injection between the two formulations. Of note, there is a large numerical difference in scores between the two studies. However, the authors have no explanation for this. Members noted that 67% of patients in the pooled population experienced greater than or equal to 1.3cm less pain following receipt of the 40mg/0.4ml versus the 40mg/0.8ml formulation (p&lt;0.001) and the mean difference in immediate pain after injection for the pooled population was -2.48 (95% CI -2.97 to -2.00; p&lt;0.001). Members noted the minimum clinically important difference in VAS pain score for acute pain is reported to be around 1.3cm (Kelly AM. Emerg Meg J 2001;18:205-7).</p><p><br></p><p>From a clinical efficacy perspective, the Committee considered the formulations appear to be comparable. Members considered from a safety perspective, any potential change in formulation may lead to alterations in protein folding and the potential for a change in antigenicity. Results from the randomised and open label extension trial regarding efficacy and safety suggest that levels of antibody formation are similar between the formulations.</p><p><br></p><p>The Committee noted the sample pen devices provided to members to assess raised no concerns regarding the redesigned pen device. The Committee considered that there may be some advantages in reduced pain and ease of use with the new formulation and device, particularly for those patients that have underlying chronic pain that may contribute to pain experienced with the injection. However, Members noted the broader significance in terms of impact on quality of life and adherence has not been explored.</p><p><br></p><p>The Committee considered there would be no issues with having both formulations on the market at the same time as all presentations are for single dose use and there would be minimal opportunity to mix these up. Members noted some additional training requirements may be necessary to support patients.</p><p><br></p><p>The Committee considered that overall there may be some small benefits from the new formulation and device for some patients, however this should not be a cost to the Pharmaceutical Budget. Members considered the impacts in terms of future costs related to patent extension and impact on the introduction of adalimumab biosimilars to the New Zealand market should be considered in any funding decision to list the new formulation of adalimumab.</p>', 'fs': '<p>The Committee noted that adalimumab 10 mg, 20 mg and 40 mg subcutaneous presentations are currently listed on Pharmaceutical Schedule, subject to a Special Authority for a range of conditions. The Committee noted that some patients experience significant pain associated with the subcutaneous injection of adalimumab with the currently listed product, however these patients are receiving treatment for chronic conditions that are associated with ongoing pain and the benefit of treatment would usually outweigh the short-term injection related pain.</p><p><br></p><p>Members noted that adalimumab appears to be a more painful injection than etanercept, however only a small number of patients report that injection associated pain was the reason they switched to another injectable biologic (Navarro-Millán et al. PLoS ONE 2016;11(3):e0149781).</p><p><br></p><p>The Committee noted that the new presentation incorporates a two-fold change to the presentation of adalimumab (Humira) to create a citrate-free (CF) formulation, in order to reduce the injection volume, and changes the auto-injector pen device and needle size to aid administration. The current formulation and device could remain available until 30 June 2019 (the end of AbbVie’s current subsidy and delisting protection), although it would be the supplier’s preference to replace the current product sooner. Members noted there may be a potential stock risk in the future if New Zealand continues to list a product that is different to other countries and that PHARMAC staff would need to assess this risk.</p><p><br></p><p>The Committee noted the supplier submitted a new medicine application to Medsafe for the new 40 mg/0.4 ml formulation in March 2016 and registration is expected by May 2017. Members noted that registration of the 10 mg and 20 mg products is not expected until the end of 2018 and these strengths would continue to be available as pre-filled syringes only.</p><p><br></p><p>The Committee noted weak evidence that citrate buffers may be associated with increased pain on subcutaneous injection in comparison with alternatives such as histidine buffer or normal saline (Larsen et al. Basic &amp; Clinical Pharmacology &amp; Toxicology 2006; 98:218–21).\\xa0</p><p><br></p><p>Members noted increased injection volume is also associated with increased pain. However, Members considered both concentrations of adalimumab are in a relatively small volume (0.4 ml and 0.8ml). A study by Heise et al. (Diabetes, Obesity and Metabolism 2014;16:971–6) suggested that there may be little difference in pain on injection of either 0.4 or 0.8 ml volume. The Committee considered that it is unclear if a change in needle gauge from 29 to 27 would significantly affect pain on injection.</p><p><br></p><p>The Committee noted four studies provided in the application regarding pain on injection (M10-867, M11-964, M12-783, and M12-159). Two studies were relatively large Phase I trials (M10-867, M12-159) where pre-filled syringes were used to administer a single dose of one of the formulations to healthy subjects. Members noted the Visual Analogue Scale (VAS) scores immediately after injection were statistically significantly higher in the users of the original formulation. However, there was significant variation between subjects as indicated by a very large standard deviation in the numeric results. Pain had diminished significantly by 15 minutes in both treatment arms. Results for both Phase I studies were similar. </p><p><br></p><p>Members noted that two Phase II trials (M11-964 and M12-783) evaluated injection pain following use of a pre-filled syringe of either the current or high-concentration formulation, in treatment naïve and pain experienced patients who had received at least 6 consecutive adalimumab doses prior to screening. Members noted that a recently published paper (Nash et al. Rheumatol Ther August 2016, published online DOI 10.1007/s40744-016-0041-3) provides more detail regarding the VAS scores and shows a statistical difference in VAS immediately after injection between the two formulations. Of note, there is a large numerical difference in scores between the two studies. However, the authors have no explanation for this. Members noted that 67% of patients in the pooled population experienced greater than or equal to 1.3cm less pain following receipt of the 40mg/0.4ml versus the 40mg/0.8ml formulation (p&lt;0.001) and the mean difference in immediate pain after injection for the pooled population was -2.48 (95% CI -2.97 to -2.00; p&lt;0.001). Members noted the minimum clinically important difference in VAS pain score for acute pain is reported to be around 1.3cm (Kelly AM. Emerg Meg J 2001;18:205-7).</p><p><br></p><p>From a clinical efficacy perspective, the Committee considered the formulations appear to be comparable. Members considered from a safety perspective, any potential change in formulation may lead to alterations in protein folding and the potential for a change in antigenicity. Results from the randomised and open label extension trial regarding efficacy and safety suggest that levels of antibody formation are similar between the formulations.</p><p><br></p><p>The Committee noted the sample pen devices provided to members to assess raised no concerns regarding the redesigned pen device. The Committee considered that there may be some advantages in reduced pain and ease of use with the new formulation and device, particularly for those patients that have underlying chronic pain that may contribute to pain experienced with the injection. However, Members noted the broader significance in terms of impact on quality of life and adherence has not been explored.</p><p><br></p><p>The Committee considered there would be no issues with having both formulations on the market at the same time as all presentations are for single dose use and there would be minimal opportunity to mix these up. Members noted some additional training requirements may be necessary to support patients.</p><p><br></p><p>The Committee considered that overall there may be some small benefits from the new formulation and device for some patients, however this should not be a cost to the Pharmaceutical Budget. Members considered the impacts in terms of future costs related to patent extension and impact on the introduction of adalimumab biosimilars to the New Zealand market should be considered in any funding decision to list the new formulation of adalimumab.</p>', 'change': None}, 'Published_Application': {'s': '<p>The Committee reviewed an application from AbbVie for the funding of a new formulation of adalimumab citrate-free and new pen device for all indications to replace the existing presentations of Humira 40mg/0.8ml in a pre-filled syringe and auto-injector.\\xa0</p>', 'fs': '<p>The Committee reviewed an application from AbbVie for the funding of a new formulation of adalimumab citrate-free and new pen device for all indications to replace the existing presentations of Humira 40mg/0.8ml in a pre-filled syringe and auto-injector.\\xa0</p>', 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': '<p>https://pharmac.govt.nz/assets/2016-11-PTAC-minutes.pdf</p>', 'fs': '<p>https://pharmac.govt.nz/assets/2016-11-PTAC-minutes.pdf</p>', 'change': None}, 'Formatted_Date': {'s': 'Nov 2016', 'fs': 'Nov 2016', 'change': None}, 'Event_Description': {'s': None, 'fs': None, 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ00000Ogl9b2AB'}, 'Id': 'a0POZ00000Ogl9b2AB', 'Event_Date__c': '2016-11-03', 'Stage__c': 'Seeking Clinical Advice', 'Links__c': '<p>https://pharmac.govt.nz/assets/2016-11-PTAC-minutes.pdf</p>', 'Formatted_Date__c': 'Nov 2016', 'Published_Recommendation__c': '<p>The Committee recommended the new formulation and device of adalimumab be listed on the Pharmaceutical Schedule if cost-neutral to the existing presentations of adalimumab, including the future costs of adalimumab with regards to patent extension and the introduction of biosimilar presentations.</p><p><br></p><p>The Committee took into account, where applicable, PHARMAC&#39;s relevant decision-making framework for these recommendations.</p>', 'Published_Application__c': '<p>The Committee reviewed an application from AbbVie for the funding of a new formulation of adalimumab citrate-free and new pen device for all indications to replace the existing presentations of Humira 40mg/0.8ml in a pre-filled syringe and auto-injector.\\xa0</p>', 'Published_Discussion__c': '<p>The Committee noted that adalimumab 10 mg, 20 mg and 40 mg subcutaneous presentations are currently listed on Pharmaceutical Schedule, subject to a Special Authority for a range of conditions. The Committee noted that some patients experience significant pain associated with the subcutaneous injection of adalimumab with the currently listed product, however these patients are receiving treatment for chronic conditions that are associated with ongoing pain and the benefit of treatment would usually outweigh the short-term injection related pain.</p><p><br></p><p>Members noted that adalimumab appears to be a more painful injection than etanercept, however only a small number of patients report that injection associated pain was the reason they switched to another injectable biologic (Navarro-Millán et al. PLoS ONE 2016;11(3):e0149781).</p><p><br></p><p>The Committee noted that the new presentation incorporates a two-fold change to the presentation of adalimumab (Humira) to create a citrate-free (CF) formulation, in order to reduce the injection volume, and changes the auto-injector pen device and needle size to aid administration. The current formulation and device could remain available until 30 June 2019 (the end of AbbVie’s current subsidy and delisting protection), although it would be the supplier’s preference to replace the current product sooner. Members noted there may be a potential stock risk in the future if New Zealand continues to list a product that is different to other countries and that PHARMAC staff would need to assess this risk.</p><p><br></p><p>The Committee noted the supplier submitted a new medicine application to Medsafe for the new 40 mg/0.4 ml formulation in March 2016 and registration is expected by May 2017. Members noted that registration of the 10 mg and 20 mg products is not expected until the end of 2018 and these strengths would continue to be available as pre-filled syringes only.</p><p><br></p><p>The Committee noted weak evidence that citrate buffers may be associated with increased pain on subcutaneous injection in comparison with alternatives such as histidine buffer or normal saline (Larsen et al. Basic &amp; Clinical Pharmacology &amp; Toxicology 2006; 98:218–21).\\xa0</p><p><br></p><p>Members noted increased injection volume is also associated with increased pain. However, Members considered both concentrations of adalimumab are in a relatively small volume (0.4 ml and 0.8ml). A study by Heise et al. (Diabetes, Obesity and Metabolism 2014;16:971–6) suggested that there may be little difference in pain on injection of either 0.4 or 0.8 ml volume. The Committee considered that it is unclear if a change in needle gauge from 29 to 27 would significantly affect pain on injection.</p><p><br></p><p>The Committee noted four studies provided in the application regarding pain on injection (M10-867, M11-964, M12-783, and M12-159). Two studies were relatively large Phase I trials (M10-867, M12-159) where pre-filled syringes were used to administer a single dose of one of the formulations to healthy subjects. Members noted the Visual Analogue Scale (VAS) scores immediately after injection were statistically significantly higher in the users of the original formulation. However, there was significant variation between subjects as indicated by a very large standard deviation in the numeric results. Pain had diminished significantly by 15 minutes in both treatment arms. Results for both Phase I studies were similar. </p><p><br></p><p>Members noted that two Phase II trials (M11-964 and M12-783) evaluated injection pain following use of a pre-filled syringe of either the current or high-concentration formulation, in treatment naïve and pain experienced patients who had received at least 6 consecutive adalimumab doses prior to screening. Members noted that a recently published paper (Nash et al. Rheumatol Ther August 2016, published online DOI 10.1007/s40744-016-0041-3) provides more detail regarding the VAS scores and shows a statistical difference in VAS immediately after injection between the two formulations. Of note, there is a large numerical difference in scores between the two studies. However, the authors have no explanation for this. Members noted that 67% of patients in the pooled population experienced greater than or equal to 1.3cm less pain following receipt of the 40mg/0.4ml versus the 40mg/0.8ml formulation (p&lt;0.001) and the mean difference in immediate pain after injection for the pooled population was -2.48 (95% CI -2.97 to -2.00; p&lt;0.001). Members noted the minimum clinically important difference in VAS pain score for acute pain is reported to be around 1.3cm (Kelly AM. Emerg Meg J 2001;18:205-7).</p><p><br></p><p>From a clinical efficacy perspective, the Committee considered the formulations appear to be comparable. Members considered from a safety perspective, any potential change in formulation may lead to alterations in protein folding and the potential for a change in antigenicity. Results from the randomised and open label extension trial regarding efficacy and safety suggest that levels of antibody formation are similar between the formulations.</p><p><br></p><p>The Committee noted the sample pen devices provided to members to assess raised no concerns regarding the redesigned pen device. The Committee considered that there may be some advantages in reduced pain and ease of use with the new formulation and device, particularly for those patients that have underlying chronic pain that may contribute to pain experienced with the injection. However, Members noted the broader significance in terms of impact on quality of life and adherence has not been explored.</p><p><br></p><p>The Committee considered there would be no issues with having both formulations on the market at the same time as all presentations are for single dose use and there would be minimal opportunity to mix these up. Members noted some additional training requirements may be necessary to support patients.</p><p><br></p><p>The Committee considered that overall there may be some small benefits from the new formulation and device for some patients, however this should not be a cost to the Pharmaceutical Budget. Members considered the impacts in terms of future costs related to patent extension and impact on the introduction of adalimumab biosimilars to the New Zealand market should be considered in any funding decision to list the new formulation of adalimumab.</p>', 'Status_History__c': 'a132P000000ArCwQAK'}, 'change': None}\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      " 82%|████████▏ | 1652/2015 [00:07<00:01, 215.10it/s]"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "{'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Oct 2017', 'fs': 'Oct 2017', 'change': None}, 'Event_Description': {'s': None, 'fs': None, 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ0000032tQR2AY'}, 'Id': 'a0POZ0000032tQR2AY', 'Event_Date__c': '2017-10-12', 'Stage__c': 'Options Compared', 'Formatted_Date__c': 'Oct 2017', 'Status_History__c': 'a132P000000ArLkQAK'}, 'change': None}\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      " 91%|█████████ | 1830/2015 [00:08<00:00, 216.75it/s]"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "{'Summary': {'s': '<p>A summary of provisional recommendations from the June 10 2025 Rare Disorders Committee meeting has been published. Within the context of treatments for rare disorders, Garadacimab was recommended with a <strong>High Priority</strong> for the treatment of hereditary angioedema, subject to Special Authority criteria.</p>', 'fs': '<p>A summary of provisional recommendations from the June 10 2025 Rare Disorders Committee meeting has been published. Within the context of treatments for rare disorders, Garadacimab was recommended with a <strong>High Priority</strong> for the treatment of hereditary angioedema, subject to Special Authority criteria.</p>', 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': '<p>https://www.pharmac.govt.nz/assets/Provisional-Summary-of-recommendations-from-June-2025-Rare-Disorders-Committee-meeting.pdf</p>', 'fs': '<p>https://www.pharmac.govt.nz/assets/Provisional-Summary-of-recommendations-from-June-2025-Rare-Disorders-Committee-meeting.pdf</p>', 'change': None}, 'Formatted_Date': {'s': 'Jul 2025', 'fs': 'Jul 2025', 'change': None}, 'Event_Description': {'s': None, 'fs': None, 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ00000VK8PX2A1'}, 'Id': 'a0POZ00000VK8PX2A1', 'Event_Date__c': '2025-07-22', 'Stage__c': 'Seeking Clinical Advice', 'Links__c': '<p>https://www.pharmac.govt.nz/assets/Provisional-Summary-of-recommendations-from-June-2025-Rare-Disorders-Committee-meeting.pdf</p>', 'Summary__c': '<p>A summary of provisional recommendations from the June 10 2025 Rare Disorders Committee meeting has been published. Within the context of treatments for rare disorders, Garadacimab was recommended with a <strong>High Priority</strong> for the treatment of hereditary angioedema, subject to Special Authority criteria.</p>', 'Formatted_Date__c': 'Jul 2025', 'Status_History__c': 'a13OZ00000Qk4L5YAJ'}, 'change': None}\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      " 93%|█████████▎| 1875/2015 [00:08<00:00, 190.04it/s]"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "{'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Dec 2012', 'fs': 'Dec 2012', 'change': None}, 'Event_Description': {'s': None, 'fs': None, 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0P2P000002ztraUAA'}, 'Id': 'a0P2P000002ztraUAA', 'Event_Date__c': '2012-12-01', 'Stage__c': 'Seeking Clinical Advice', 'Formatted_Date__c': 'Dec 2012', 'Status_History__c': 'a132P000000AqG0QAK'}, 'change': None}\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      " 99%|█████████▊| 1988/2015 [00:09<00:00, 213.29it/s]"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "{'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Jun 2013', 'fs': 'Jun 2013', 'change': None}, 'Event_Description': {'s': None, 'fs': None, 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ00000F3gLZ2AZ'}, 'Id': 'a0POZ00000F3gLZ2AZ', 'Event_Date__c': '2013-06-01', 'Stage__c': 'Options Compared', 'Formatted_Date__c': 'Jun 2013', 'Status_History__c': 'a132P000000AqQ1QAK'}, 'change': None}\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "100%|██████████| 2015/2015 [00:09<00:00, 214.15it/s]\n"
     ]
    },
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>Id</th>\n",
       "      <th>Name</th>\n",
       "      <th>Applications__c</th>\n",
       "      <th>Brand_Name__c</th>\n",
       "      <th>Chemical_Name__c</th>\n",
       "      <th>Applicants__c</th>\n",
       "      <th>Funding_requested_for__c</th>\n",
       "      <th>Stage__c</th>\n",
       "      <th>Pharmaceutical__c</th>\n",
       "      <th>Community_URL__c</th>\n",
       "      <th>Therapeutic_group__c</th>\n",
       "      <th>Application Received date</th>\n",
       "      <th>Last Update date</th>\n",
       "      <th>Days elapsed between application and last update</th>\n",
       "      <th>Application Received dates</th>\n",
       "      <th>Seeking Clinical Advice dates</th>\n",
       "      <th>Under Assessment dates</th>\n",
       "      <th>Options Compared dates</th>\n",
       "      <th>Under Consultation dates</th>\n",
       "      <th>Reviewing Consultation Feedback dates</th>\n",
       "      <th>Decision dates</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>688</th>\n",
       "      <td>a0R2P000000LmkWUAS</td>\n",
       "      <td>Risperidone tablets</td>\n",
       "      <td>A-01127</td>\n",
       "      <td>Risperdal</td>\n",
       "      <td>Risperidone tablets</td>\n",
       "      <td>Janssen</td>\n",
       "      <td>Schizophrenia</td>\n",
       "      <td>Decision</td>\n",
       "      <td>Risperidone tablets (Risperdal)</td>\n",
       "      <td>https://connect.pharmac.govt.nz/apptracker/s/a...</td>\n",
       "      <td>Nervous System</td>\n",
       "      <td>1994-04-01</td>\n",
       "      <td>1995-10-01</td>\n",
       "      <td>548</td>\n",
       "      <td>1994-04-01:Application received</td>\n",
       "      <td>1994-04-01:Clinical advice required\\r\\n1994-06...</td>\n",
       "      <td>1994-12-01:Working to compare options\\r\\n1995-...</td>\n",
       "      <td>1994-09-01:The relative ranking of the pharmac...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1995-10-01:The funding application has been Ap...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>584</th>\n",
       "      <td>a0R2P000000LmjmUAC</td>\n",
       "      <td>Gabapentin</td>\n",
       "      <td>A-01197</td>\n",
       "      <td>Neurontin</td>\n",
       "      <td>Gabapentin</td>\n",
       "      <td>Parke Davis</td>\n",
       "      <td>Partial seizures in patients who have not achi...</td>\n",
       "      <td>Decision</td>\n",
       "      <td>Gabapentin (Neurontin)</td>\n",
       "      <td>https://connect.pharmac.govt.nz/apptracker/s/a...</td>\n",
       "      <td>Nervous System</td>\n",
       "      <td>1994-08-01</td>\n",
       "      <td>2001-03-01</td>\n",
       "      <td>2404</td>\n",
       "      <td>1994-08-01:Application received</td>\n",
       "      <td>1995-02-01:Clinical advice required\\r\\n1995-03...</td>\n",
       "      <td>1995-03-01:Working to compare options</td>\n",
       "      <td>1995-05-01:The relative ranking of the pharmac...</td>\n",
       "      <td>2001-01-01:Public consultation for this applic...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>2001-03-01:The funding application has been Ap...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>982</th>\n",
       "      <td>a0R2P000000LmThUAK</td>\n",
       "      <td>Somatropin - Growth Hormone</td>\n",
       "      <td>A-01165</td>\n",
       "      <td>Genotropin</td>\n",
       "      <td>Somatropin - Growth Hormone</td>\n",
       "      <td>Clinician</td>\n",
       "      <td>Adult  and adolescent  patients with growth ho...</td>\n",
       "      <td>Decision</td>\n",
       "      <td>Somatropin - Growth Hormone (Genotropin)</td>\n",
       "      <td>https://connect.pharmac.govt.nz/apptracker/s/a...</td>\n",
       "      <td>Hormone Preparations - Systemic Excluding Cont...</td>\n",
       "      <td>1995-09-01</td>\n",
       "      <td>2005-09-01</td>\n",
       "      <td>3653</td>\n",
       "      <td>1995-09-01:Application received</td>\n",
       "      <td>1995-09-01:Clinical advice required\\r\\n1995-11...</td>\n",
       "      <td>1996-11-01:Working to compare options</td>\n",
       "      <td>1995-11-01:The relative ranking of the pharmac...</td>\n",
       "      <td>2009-10-01:Public consultation for this applic...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>2005-09-01:The funding application has been Ap...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>593</th>\n",
       "      <td>a0R2P000000Lmo2UAC</td>\n",
       "      <td>Interferon beta-1-beta</td>\n",
       "      <td>A-01183</td>\n",
       "      <td>Betaferon</td>\n",
       "      <td>Interferon beta-1-beta</td>\n",
       "      <td>Bayer</td>\n",
       "      <td>Relapsing remitting multiple sclerosis</td>\n",
       "      <td>Decision</td>\n",
       "      <td>Interferon beta-1-beta (Betaferon)</td>\n",
       "      <td>https://connect.pharmac.govt.nz/apptracker/s/a...</td>\n",
       "      <td>Nervous System</td>\n",
       "      <td>1996-01-01</td>\n",
       "      <td>1999-07-01</td>\n",
       "      <td>1277</td>\n",
       "      <td>1996-01-01:Application received</td>\n",
       "      <td>1996-01-01:Clinical advice required\\r\\n1996-03...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1999-05-01:The relative ranking of the pharmac...</td>\n",
       "      <td>1999-05-01:Public consultation for this applic...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1999-07-01:The funding application has been Ap...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1407</th>\n",
       "      <td>a0R2P000000LmqWUAS</td>\n",
       "      <td>Anastrozole</td>\n",
       "      <td>A-01169</td>\n",
       "      <td>Arimidex</td>\n",
       "      <td>Anastrozole</td>\n",
       "      <td>AstraZeneca</td>\n",
       "      <td>Third line treatment of advanced breast cancer</td>\n",
       "      <td>Decision</td>\n",
       "      <td>Anastrozole (Arimidex)</td>\n",
       "      <td>https://connect.pharmac.govt.nz/apptracker/s/a...</td>\n",
       "      <td>Oncology Agents and Immunosuppressants</td>\n",
       "      <td>1997-02-01</td>\n",
       "      <td>1998-12-01</td>\n",
       "      <td>668</td>\n",
       "      <td>1997-02-01:Application received</td>\n",
       "      <td>1997-02-01:Clinical advice required\\r\\n1997-05...</td>\n",
       "      <td>1997-05-01:Working to compare options</td>\n",
       "      <td>1998-10-01:The relative ranking of the pharmac...</td>\n",
       "      <td>1998-10-01:Public consultation for this applic...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1998-12-01:The funding application has been Ap...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>...</th>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1282</th>\n",
       "      <td>a0ROZ00000Dms532AB</td>\n",
       "      <td>Riociguat</td>\n",
       "      <td>A-05544</td>\n",
       "      <td>ADEMPAS</td>\n",
       "      <td>Riociguat</td>\n",
       "      <td>Clinician</td>\n",
       "      <td>Chronic Thromboembolic Pulmonary Hypertension ...</td>\n",
       "      <td>Seeking Clinical Advice</td>\n",
       "      <td>Riociguat (ADEMPAS)</td>\n",
       "      <td>https://connect.pharmac.govt.nz/apptracker/s/a...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>2025-10-28</td>\n",
       "      <td>2026-02-02</td>\n",
       "      <td>97</td>\n",
       "      <td>2025-10-28:Application received</td>\n",
       "      <td>2026-02-02:Clinical advice required</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1770</th>\n",
       "      <td>a0ROZ00000DL1uT2AT</td>\n",
       "      <td>Mepolizumab</td>\n",
       "      <td>A-05540</td>\n",
       "      <td>Nucala</td>\n",
       "      <td>Mepolizumab</td>\n",
       "      <td>GLAXOSMITHKLINE NZ LIMITED</td>\n",
       "      <td>Inadequately controlled chronic obstructive pu...</td>\n",
       "      <td>Seeking Clinical Advice</td>\n",
       "      <td>Mepolizumab (Nucala)</td>\n",
       "      <td>https://connect.pharmac.govt.nz/apptracker/s/a...</td>\n",
       "      <td>Respiratory System and Allergies</td>\n",
       "      <td>2025-10-31</td>\n",
       "      <td>2026-01-09</td>\n",
       "      <td>70</td>\n",
       "      <td>2025-10-31:Application received</td>\n",
       "      <td>2026-01-09:Clinical advice required</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1841</th>\n",
       "      <td>a0ROZ00000DGeA52AL</td>\n",
       "      <td>Upadacitinib</td>\n",
       "      <td>A-05543</td>\n",
       "      <td>Rinvoq</td>\n",
       "      <td>Upadacitinib</td>\n",
       "      <td>ABBVIE LIMITED</td>\n",
       "      <td>Giant cell ateritis (GCA), glucocorticoid tape...</td>\n",
       "      <td>Seeking Clinical Advice</td>\n",
       "      <td>Upadacitinib (Rinvoq)</td>\n",
       "      <td>https://connect.pharmac.govt.nz/apptracker/s/a...</td>\n",
       "      <td>Musculoskeletal System</td>\n",
       "      <td>2025-10-31</td>\n",
       "      <td>2026-01-05</td>\n",
       "      <td>66</td>\n",
       "      <td>2025-10-31:Application received</td>\n",
       "      <td>2026-01-05:Clinical advice required</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1919</th>\n",
       "      <td>a0ROZ00000DKizt2AD</td>\n",
       "      <td>pembrolizumab</td>\n",
       "      <td>A-05472</td>\n",
       "      <td>KEYTRUDA</td>\n",
       "      <td>pembrolizumab</td>\n",
       "      <td>MERCK SHARP &amp; DOHME (NEW ZEALAND) LIMITED</td>\n",
       "      <td>Squamous Cell Carcinoma of the Head and Neck, ...</td>\n",
       "      <td>Seeking Clinical Advice</td>\n",
       "      <td>pembrolizumab (KEYTRUDA)</td>\n",
       "      <td>https://connect.pharmac.govt.nz/apptracker/s/a...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>2025-12-19</td>\n",
       "      <td>2026-01-09</td>\n",
       "      <td>21</td>\n",
       "      <td>2025-12-19:Application received</td>\n",
       "      <td>2026-01-09:Clinical advice required</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1126</th>\n",
       "      <td>a0ROZ00000DoZ9Z2AV</td>\n",
       "      <td>Emicizumab</td>\n",
       "      <td>A-05466</td>\n",
       "      <td>Hemlibra</td>\n",
       "      <td>Emicizumab</td>\n",
       "      <td>Clinician</td>\n",
       "      <td>Haemophilia A, moderate severity, severe bleed...</td>\n",
       "      <td>Seeking Clinical Advice</td>\n",
       "      <td>Emicizumab (Hemlibra)</td>\n",
       "      <td>https://connect.pharmac.govt.nz/apptracker/s/a...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>2026-01-14</td>\n",
       "      <td>2026-02-03</td>\n",
       "      <td>20</td>\n",
       "      <td>2026-01-14:Application received</td>\n",
       "      <td>2026-02-03:Clinical advice required</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>2015 rows × 21 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "                      Id                         Name Applications__c  \\\n",
       "688   a0R2P000000LmkWUAS          Risperidone tablets         A-01127   \n",
       "584   a0R2P000000LmjmUAC                   Gabapentin         A-01197   \n",
       "982   a0R2P000000LmThUAK  Somatropin - Growth Hormone         A-01165   \n",
       "593   a0R2P000000Lmo2UAC       Interferon beta-1-beta         A-01183   \n",
       "1407  a0R2P000000LmqWUAS                  Anastrozole         A-01169   \n",
       "...                  ...                          ...             ...   \n",
       "1282  a0ROZ00000Dms532AB                    Riociguat         A-05544   \n",
       "1770  a0ROZ00000DL1uT2AT                  Mepolizumab         A-05540   \n",
       "1841  a0ROZ00000DGeA52AL                 Upadacitinib         A-05543   \n",
       "1919  a0ROZ00000DKizt2AD                pembrolizumab         A-05472   \n",
       "1126  a0ROZ00000DoZ9Z2AV                   Emicizumab         A-05466   \n",
       "\n",
       "     Brand_Name__c             Chemical_Name__c  \\\n",
       "688      Risperdal          Risperidone tablets   \n",
       "584      Neurontin                   Gabapentin   \n",
       "982     Genotropin  Somatropin - Growth Hormone   \n",
       "593      Betaferon       Interferon beta-1-beta   \n",
       "1407      Arimidex                  Anastrozole   \n",
       "...            ...                          ...   \n",
       "1282       ADEMPAS                    Riociguat   \n",
       "1770        Nucala                  Mepolizumab   \n",
       "1841        Rinvoq                 Upadacitinib   \n",
       "1919      KEYTRUDA                pembrolizumab   \n",
       "1126      Hemlibra                   Emicizumab   \n",
       "\n",
       "                                  Applicants__c  \\\n",
       "688                                     Janssen   \n",
       "584                                 Parke Davis   \n",
       "982                                   Clinician   \n",
       "593                                       Bayer   \n",
       "1407                                AstraZeneca   \n",
       "...                                         ...   \n",
       "1282                                  Clinician   \n",
       "1770                 GLAXOSMITHKLINE NZ LIMITED   \n",
       "1841                             ABBVIE LIMITED   \n",
       "1919  MERCK SHARP & DOHME (NEW ZEALAND) LIMITED   \n",
       "1126                                  Clinician   \n",
       "\n",
       "                               Funding_requested_for__c  \\\n",
       "688                                       Schizophrenia   \n",
       "584   Partial seizures in patients who have not achi...   \n",
       "982   Adult  and adolescent  patients with growth ho...   \n",
       "593              Relapsing remitting multiple sclerosis   \n",
       "1407     Third line treatment of advanced breast cancer   \n",
       "...                                                 ...   \n",
       "1282  Chronic Thromboembolic Pulmonary Hypertension ...   \n",
       "1770  Inadequately controlled chronic obstructive pu...   \n",
       "1841  Giant cell ateritis (GCA), glucocorticoid tape...   \n",
       "1919  Squamous Cell Carcinoma of the Head and Neck, ...   \n",
       "1126  Haemophilia A, moderate severity, severe bleed...   \n",
       "\n",
       "                     Stage__c                         Pharmaceutical__c  \\\n",
       "688                  Decision           Risperidone tablets (Risperdal)   \n",
       "584                  Decision                    Gabapentin (Neurontin)   \n",
       "982                  Decision  Somatropin - Growth Hormone (Genotropin)   \n",
       "593                  Decision        Interferon beta-1-beta (Betaferon)   \n",
       "1407                 Decision                    Anastrozole (Arimidex)   \n",
       "...                       ...                                       ...   \n",
       "1282  Seeking Clinical Advice                       Riociguat (ADEMPAS)   \n",
       "1770  Seeking Clinical Advice                      Mepolizumab (Nucala)   \n",
       "1841  Seeking Clinical Advice                     Upadacitinib (Rinvoq)   \n",
       "1919  Seeking Clinical Advice                  pembrolizumab (KEYTRUDA)   \n",
       "1126  Seeking Clinical Advice                     Emicizumab (Hemlibra)   \n",
       "\n",
       "                                       Community_URL__c  \\\n",
       "688   https://connect.pharmac.govt.nz/apptracker/s/a...   \n",
       "584   https://connect.pharmac.govt.nz/apptracker/s/a...   \n",
       "982   https://connect.pharmac.govt.nz/apptracker/s/a...   \n",
       "593   https://connect.pharmac.govt.nz/apptracker/s/a...   \n",
       "1407  https://connect.pharmac.govt.nz/apptracker/s/a...   \n",
       "...                                                 ...   \n",
       "1282  https://connect.pharmac.govt.nz/apptracker/s/a...   \n",
       "1770  https://connect.pharmac.govt.nz/apptracker/s/a...   \n",
       "1841  https://connect.pharmac.govt.nz/apptracker/s/a...   \n",
       "1919  https://connect.pharmac.govt.nz/apptracker/s/a...   \n",
       "1126  https://connect.pharmac.govt.nz/apptracker/s/a...   \n",
       "\n",
       "                                   Therapeutic_group__c  \\\n",
       "688                                      Nervous System   \n",
       "584                                      Nervous System   \n",
       "982   Hormone Preparations - Systemic Excluding Cont...   \n",
       "593                                      Nervous System   \n",
       "1407             Oncology Agents and Immunosuppressants   \n",
       "...                                                 ...   \n",
       "1282                                                NaN   \n",
       "1770                   Respiratory System and Allergies   \n",
       "1841                             Musculoskeletal System   \n",
       "1919                                                NaN   \n",
       "1126                                                NaN   \n",
       "\n",
       "     Application Received date Last Update date  \\\n",
       "688                 1994-04-01       1995-10-01   \n",
       "584                 1994-08-01       2001-03-01   \n",
       "982                 1995-09-01       2005-09-01   \n",
       "593                 1996-01-01       1999-07-01   \n",
       "1407                1997-02-01       1998-12-01   \n",
       "...                        ...              ...   \n",
       "1282                2025-10-28       2026-02-02   \n",
       "1770                2025-10-31       2026-01-09   \n",
       "1841                2025-10-31       2026-01-05   \n",
       "1919                2025-12-19       2026-01-09   \n",
       "1126                2026-01-14       2026-02-03   \n",
       "\n",
       "      Days elapsed between application and last update  \\\n",
       "688                                                548   \n",
       "584                                               2404   \n",
       "982                                               3653   \n",
       "593                                               1277   \n",
       "1407                                               668   \n",
       "...                                                ...   \n",
       "1282                                                97   \n",
       "1770                                                70   \n",
       "1841                                                66   \n",
       "1919                                                21   \n",
       "1126                                                20   \n",
       "\n",
       "           Application Received dates  \\\n",
       "688   1994-04-01:Application received   \n",
       "584   1994-08-01:Application received   \n",
       "982   1995-09-01:Application received   \n",
       "593   1996-01-01:Application received   \n",
       "1407  1997-02-01:Application received   \n",
       "...                               ...   \n",
       "1282  2025-10-28:Application received   \n",
       "1770  2025-10-31:Application received   \n",
       "1841  2025-10-31:Application received   \n",
       "1919  2025-12-19:Application received   \n",
       "1126  2026-01-14:Application received   \n",
       "\n",
       "                          Seeking Clinical Advice dates  \\\n",
       "688   1994-04-01:Clinical advice required\\r\\n1994-06...   \n",
       "584   1995-02-01:Clinical advice required\\r\\n1995-03...   \n",
       "982   1995-09-01:Clinical advice required\\r\\n1995-11...   \n",
       "593   1996-01-01:Clinical advice required\\r\\n1996-03...   \n",
       "1407  1997-02-01:Clinical advice required\\r\\n1997-05...   \n",
       "...                                                 ...   \n",
       "1282                2026-02-02:Clinical advice required   \n",
       "1770                2026-01-09:Clinical advice required   \n",
       "1841                2026-01-05:Clinical advice required   \n",
       "1919                2026-01-09:Clinical advice required   \n",
       "1126                2026-02-03:Clinical advice required   \n",
       "\n",
       "                                 Under Assessment dates  \\\n",
       "688   1994-12-01:Working to compare options\\r\\n1995-...   \n",
       "584               1995-03-01:Working to compare options   \n",
       "982               1996-11-01:Working to compare options   \n",
       "593                                                 NaN   \n",
       "1407              1997-05-01:Working to compare options   \n",
       "...                                                 ...   \n",
       "1282                                                NaN   \n",
       "1770                                                NaN   \n",
       "1841                                                NaN   \n",
       "1919                                                NaN   \n",
       "1126                                                NaN   \n",
       "\n",
       "                                 Options Compared dates  \\\n",
       "688   1994-09-01:The relative ranking of the pharmac...   \n",
       "584   1995-05-01:The relative ranking of the pharmac...   \n",
       "982   1995-11-01:The relative ranking of the pharmac...   \n",
       "593   1999-05-01:The relative ranking of the pharmac...   \n",
       "1407  1998-10-01:The relative ranking of the pharmac...   \n",
       "...                                                 ...   \n",
       "1282                                                NaN   \n",
       "1770                                                NaN   \n",
       "1841                                                NaN   \n",
       "1919                                                NaN   \n",
       "1126                                                NaN   \n",
       "\n",
       "                               Under Consultation dates  \\\n",
       "688                                                 NaN   \n",
       "584   2001-01-01:Public consultation for this applic...   \n",
       "982   2009-10-01:Public consultation for this applic...   \n",
       "593   1999-05-01:Public consultation for this applic...   \n",
       "1407  1998-10-01:Public consultation for this applic...   \n",
       "...                                                 ...   \n",
       "1282                                                NaN   \n",
       "1770                                                NaN   \n",
       "1841                                                NaN   \n",
       "1919                                                NaN   \n",
       "1126                                                NaN   \n",
       "\n",
       "     Reviewing Consultation Feedback dates  \\\n",
       "688                                    NaN   \n",
       "584                                    NaN   \n",
       "982                                    NaN   \n",
       "593                                    NaN   \n",
       "1407                                   NaN   \n",
       "...                                    ...   \n",
       "1282                                   NaN   \n",
       "1770                                   NaN   \n",
       "1841                                   NaN   \n",
       "1919                                   NaN   \n",
       "1126                                   NaN   \n",
       "\n",
       "                                         Decision dates  \n",
       "688   1995-10-01:The funding application has been Ap...  \n",
       "584   2001-03-01:The funding application has been Ap...  \n",
       "982   2005-09-01:The funding application has been Ap...  \n",
       "593   1999-07-01:The funding application has been Ap...  \n",
       "1407  1998-12-01:The funding application has been Ap...  \n",
       "...                                                 ...  \n",
       "1282                                                NaN  \n",
       "1770                                                NaN  \n",
       "1841                                                NaN  \n",
       "1919                                                NaN  \n",
       "1126                                                NaN  \n",
       "\n",
       "[2015 rows x 21 columns]"
      ]
     },
     "execution_count": 4,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "rows = []\n",
    "for i, row in tqdm(df.iterrows(), total=len(df)):\n",
    "    events = pd.read_json(f\"applications/{row.Id}.json\").dropna()\n",
    "    start = pd.to_datetime(events.events.iloc[0][0][\"e\"][\"Event_Date__c\"])\n",
    "    end = pd.to_datetime(events.events.iloc[-1][0][\"e\"][\"Event_Date__c\"])\n",
    "    delta = end - start\n",
    "    row[\"Application Received date\"] = start\n",
    "    row[\"Last Update date\"] = end\n",
    "    row[\"Days elapsed between application and last update\"] = delta.days\n",
    "    for stage in events.events:\n",
    "        stage_events = []\n",
    "        for event in stage:\n",
    "            try:\n",
    "                stage_events.append(event[\"e\"][\"Event_Date__c\"] + \":\" + event[\"e\"][\"Event_Description__c\"])\n",
    "            except KeyError:\n",
    "                print(event)\n",
    "        row[event[\"e\"][\"Stage__c\"] + \" dates\"] = \"\\r\\n\".join(stage_events)\n",
    "    rows.append(row)\n",
    "\n",
    "df = pd.DataFrame(rows)\n",
    "df.sort_values(\"Application Received date\", inplace=True)\n",
    "df"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 5,
   "id": "aa4aa574",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "['Id',\n",
       " 'Name',\n",
       " 'Applications__c',\n",
       " 'Brand_Name__c',\n",
       " 'Chemical_Name__c',\n",
       " 'Applicants__c',\n",
       " 'Funding_requested_for__c',\n",
       " 'Stage__c',\n",
       " 'Pharmaceutical__c',\n",
       " 'Community_URL__c',\n",
       " 'Therapeutic_group__c',\n",
       " 'Application Received date',\n",
       " 'Last Update date',\n",
       " 'Days elapsed between application and last update',\n",
       " 'Application Received dates',\n",
       " 'Seeking Clinical Advice dates',\n",
       " 'Under Assessment dates',\n",
       " 'Options Compared dates',\n",
       " 'Under Consultation dates',\n",
       " 'Reviewing Consultation Feedback dates',\n",
       " 'Decision dates']"
      ]
     },
     "execution_count": 5,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "cols = ['Id', 'Name', 'Applications__c', 'Brand_Name__c', 'Chemical_Name__c',\n",
    "       'Applicants__c', 'Funding_requested_for__c', 'Stage__c',\n",
    "       'Pharmaceutical__c', 'Community_URL__c', 'Therapeutic_group__c',\n",
    "       'Application Received date', 'Last Update date',\n",
    "       'Days elapsed between application and last update',\n",
    "       'Application Received dates', 'Seeking Clinical Advice dates',\n",
    "       'Under Assessment dates', 'Options Compared dates', \n",
    "       'Under Consultation dates', 'Reviewing Consultation Feedback dates', 'Decision dates']\n",
    "cols"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 6,
   "id": "75a00661",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>Id</th>\n",
       "      <th>Name</th>\n",
       "      <th>Applications__c</th>\n",
       "      <th>Brand_Name__c</th>\n",
       "      <th>Chemical_Name__c</th>\n",
       "      <th>Applicants__c</th>\n",
       "      <th>Funding_requested_for__c</th>\n",
       "      <th>Stage__c</th>\n",
       "      <th>Pharmaceutical__c</th>\n",
       "      <th>Community_URL__c</th>\n",
       "      <th>Therapeutic_group__c</th>\n",
       "      <th>Application Received date</th>\n",
       "      <th>Last Update date</th>\n",
       "      <th>Days elapsed between application and last update</th>\n",
       "      <th>Application Received dates</th>\n",
       "      <th>Seeking Clinical Advice dates</th>\n",
       "      <th>Under Assessment dates</th>\n",
       "      <th>Options Compared dates</th>\n",
       "      <th>Under Consultation dates</th>\n",
       "      <th>Reviewing Consultation Feedback dates</th>\n",
       "      <th>Decision dates</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>688</th>\n",
       "      <td>a0R2P000000LmkWUAS</td>\n",
       "      <td>Risperidone tablets</td>\n",
       "      <td>A-01127</td>\n",
       "      <td>Risperdal</td>\n",
       "      <td>Risperidone tablets</td>\n",
       "      <td>Janssen</td>\n",
       "      <td>Schizophrenia</td>\n",
       "      <td>Decision</td>\n",
       "      <td>Risperidone tablets (Risperdal)</td>\n",
       "      <td>https://connect.pharmac.govt.nz/apptracker/s/a...</td>\n",
       "      <td>Nervous System</td>\n",
       "      <td>1994-04-01</td>\n",
       "      <td>1995-10-01</td>\n",
       "      <td>548</td>\n",
       "      <td>1994-04-01:Application received</td>\n",
       "      <td>1994-04-01:Clinical advice required\\r\\n1994-06...</td>\n",
       "      <td>1994-12-01:Working to compare options\\r\\n1995-...</td>\n",
       "      <td>1994-09-01:The relative ranking of the pharmac...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1995-10-01:The funding application has been Ap...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>584</th>\n",
       "      <td>a0R2P000000LmjmUAC</td>\n",
       "      <td>Gabapentin</td>\n",
       "      <td>A-01197</td>\n",
       "      <td>Neurontin</td>\n",
       "      <td>Gabapentin</td>\n",
       "      <td>Parke Davis</td>\n",
       "      <td>Partial seizures in patients who have not achi...</td>\n",
       "      <td>Decision</td>\n",
       "      <td>Gabapentin (Neurontin)</td>\n",
       "      <td>https://connect.pharmac.govt.nz/apptracker/s/a...</td>\n",
       "      <td>Nervous System</td>\n",
       "      <td>1994-08-01</td>\n",
       "      <td>2001-03-01</td>\n",
       "      <td>2404</td>\n",
       "      <td>1994-08-01:Application received</td>\n",
       "      <td>1995-02-01:Clinical advice required\\r\\n1995-03...</td>\n",
       "      <td>1995-03-01:Working to compare options</td>\n",
       "      <td>1995-05-01:The relative ranking of the pharmac...</td>\n",
       "      <td>2001-01-01:Public consultation for this applic...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>2001-03-01:The funding application has been Ap...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>982</th>\n",
       "      <td>a0R2P000000LmThUAK</td>\n",
       "      <td>Somatropin - Growth Hormone</td>\n",
       "      <td>A-01165</td>\n",
       "      <td>Genotropin</td>\n",
       "      <td>Somatropin - Growth Hormone</td>\n",
       "      <td>Clinician</td>\n",
       "      <td>Adult  and adolescent  patients with growth ho...</td>\n",
       "      <td>Decision</td>\n",
       "      <td>Somatropin - Growth Hormone (Genotropin)</td>\n",
       "      <td>https://connect.pharmac.govt.nz/apptracker/s/a...</td>\n",
       "      <td>Hormone Preparations - Systemic Excluding Cont...</td>\n",
       "      <td>1995-09-01</td>\n",
       "      <td>2005-09-01</td>\n",
       "      <td>3653</td>\n",
       "      <td>1995-09-01:Application received</td>\n",
       "      <td>1995-09-01:Clinical advice required\\r\\n1995-11...</td>\n",
       "      <td>1996-11-01:Working to compare options</td>\n",
       "      <td>1995-11-01:The relative ranking of the pharmac...</td>\n",
       "      <td>2009-10-01:Public consultation for this applic...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>2005-09-01:The funding application has been Ap...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>593</th>\n",
       "      <td>a0R2P000000Lmo2UAC</td>\n",
       "      <td>Interferon beta-1-beta</td>\n",
       "      <td>A-01183</td>\n",
       "      <td>Betaferon</td>\n",
       "      <td>Interferon beta-1-beta</td>\n",
       "      <td>Bayer</td>\n",
       "      <td>Relapsing remitting multiple sclerosis</td>\n",
       "      <td>Decision</td>\n",
       "      <td>Interferon beta-1-beta (Betaferon)</td>\n",
       "      <td>https://connect.pharmac.govt.nz/apptracker/s/a...</td>\n",
       "      <td>Nervous System</td>\n",
       "      <td>1996-01-01</td>\n",
       "      <td>1999-07-01</td>\n",
       "      <td>1277</td>\n",
       "      <td>1996-01-01:Application received</td>\n",
       "      <td>1996-01-01:Clinical advice required\\r\\n1996-03...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1999-05-01:The relative ranking of the pharmac...</td>\n",
       "      <td>1999-05-01:Public consultation for this applic...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1999-07-01:The funding application has been Ap...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1407</th>\n",
       "      <td>a0R2P000000LmqWUAS</td>\n",
       "      <td>Anastrozole</td>\n",
       "      <td>A-01169</td>\n",
       "      <td>Arimidex</td>\n",
       "      <td>Anastrozole</td>\n",
       "      <td>AstraZeneca</td>\n",
       "      <td>Third line treatment of advanced breast cancer</td>\n",
       "      <td>Decision</td>\n",
       "      <td>Anastrozole (Arimidex)</td>\n",
       "      <td>https://connect.pharmac.govt.nz/apptracker/s/a...</td>\n",
       "      <td>Oncology Agents and Immunosuppressants</td>\n",
       "      <td>1997-02-01</td>\n",
       "      <td>1998-12-01</td>\n",
       "      <td>668</td>\n",
       "      <td>1997-02-01:Application received</td>\n",
       "      <td>1997-02-01:Clinical advice required\\r\\n1997-05...</td>\n",
       "      <td>1997-05-01:Working to compare options</td>\n",
       "      <td>1998-10-01:The relative ranking of the pharmac...</td>\n",
       "      <td>1998-10-01:Public consultation for this applic...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1998-12-01:The funding application has been Ap...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>...</th>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1282</th>\n",
       "      <td>a0ROZ00000Dms532AB</td>\n",
       "      <td>Riociguat</td>\n",
       "      <td>A-05544</td>\n",
       "      <td>ADEMPAS</td>\n",
       "      <td>Riociguat</td>\n",
       "      <td>Clinician</td>\n",
       "      <td>Chronic Thromboembolic Pulmonary Hypertension ...</td>\n",
       "      <td>Seeking Clinical Advice</td>\n",
       "      <td>Riociguat (ADEMPAS)</td>\n",
       "      <td>https://connect.pharmac.govt.nz/apptracker/s/a...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>2025-10-28</td>\n",
       "      <td>2026-02-02</td>\n",
       "      <td>97</td>\n",
       "      <td>2025-10-28:Application received</td>\n",
       "      <td>2026-02-02:Clinical advice required</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1770</th>\n",
       "      <td>a0ROZ00000DL1uT2AT</td>\n",
       "      <td>Mepolizumab</td>\n",
       "      <td>A-05540</td>\n",
       "      <td>Nucala</td>\n",
       "      <td>Mepolizumab</td>\n",
       "      <td>GLAXOSMITHKLINE NZ LIMITED</td>\n",
       "      <td>Inadequately controlled chronic obstructive pu...</td>\n",
       "      <td>Seeking Clinical Advice</td>\n",
       "      <td>Mepolizumab (Nucala)</td>\n",
       "      <td>https://connect.pharmac.govt.nz/apptracker/s/a...</td>\n",
       "      <td>Respiratory System and Allergies</td>\n",
       "      <td>2025-10-31</td>\n",
       "      <td>2026-01-09</td>\n",
       "      <td>70</td>\n",
       "      <td>2025-10-31:Application received</td>\n",
       "      <td>2026-01-09:Clinical advice required</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1841</th>\n",
       "      <td>a0ROZ00000DGeA52AL</td>\n",
       "      <td>Upadacitinib</td>\n",
       "      <td>A-05543</td>\n",
       "      <td>Rinvoq</td>\n",
       "      <td>Upadacitinib</td>\n",
       "      <td>ABBVIE LIMITED</td>\n",
       "      <td>Giant cell ateritis (GCA), glucocorticoid tape...</td>\n",
       "      <td>Seeking Clinical Advice</td>\n",
       "      <td>Upadacitinib (Rinvoq)</td>\n",
       "      <td>https://connect.pharmac.govt.nz/apptracker/s/a...</td>\n",
       "      <td>Musculoskeletal System</td>\n",
       "      <td>2025-10-31</td>\n",
       "      <td>2026-01-05</td>\n",
       "      <td>66</td>\n",
       "      <td>2025-10-31:Application received</td>\n",
       "      <td>2026-01-05:Clinical advice required</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1919</th>\n",
       "      <td>a0ROZ00000DKizt2AD</td>\n",
       "      <td>pembrolizumab</td>\n",
       "      <td>A-05472</td>\n",
       "      <td>KEYTRUDA</td>\n",
       "      <td>pembrolizumab</td>\n",
       "      <td>MERCK SHARP &amp; DOHME (NEW ZEALAND) LIMITED</td>\n",
       "      <td>Squamous Cell Carcinoma of the Head and Neck, ...</td>\n",
       "      <td>Seeking Clinical Advice</td>\n",
       "      <td>pembrolizumab (KEYTRUDA)</td>\n",
       "      <td>https://connect.pharmac.govt.nz/apptracker/s/a...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>2025-12-19</td>\n",
       "      <td>2026-01-09</td>\n",
       "      <td>21</td>\n",
       "      <td>2025-12-19:Application received</td>\n",
       "      <td>2026-01-09:Clinical advice required</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1126</th>\n",
       "      <td>a0ROZ00000DoZ9Z2AV</td>\n",
       "      <td>Emicizumab</td>\n",
       "      <td>A-05466</td>\n",
       "      <td>Hemlibra</td>\n",
       "      <td>Emicizumab</td>\n",
       "      <td>Clinician</td>\n",
       "      <td>Haemophilia A, moderate severity, severe bleed...</td>\n",
       "      <td>Seeking Clinical Advice</td>\n",
       "      <td>Emicizumab (Hemlibra)</td>\n",
       "      <td>https://connect.pharmac.govt.nz/apptracker/s/a...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>2026-01-14</td>\n",
       "      <td>2026-02-03</td>\n",
       "      <td>20</td>\n",
       "      <td>2026-01-14:Application received</td>\n",
       "      <td>2026-02-03:Clinical advice required</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>2015 rows × 21 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "                      Id                         Name Applications__c  \\\n",
       "688   a0R2P000000LmkWUAS          Risperidone tablets         A-01127   \n",
       "584   a0R2P000000LmjmUAC                   Gabapentin         A-01197   \n",
       "982   a0R2P000000LmThUAK  Somatropin - Growth Hormone         A-01165   \n",
       "593   a0R2P000000Lmo2UAC       Interferon beta-1-beta         A-01183   \n",
       "1407  a0R2P000000LmqWUAS                  Anastrozole         A-01169   \n",
       "...                  ...                          ...             ...   \n",
       "1282  a0ROZ00000Dms532AB                    Riociguat         A-05544   \n",
       "1770  a0ROZ00000DL1uT2AT                  Mepolizumab         A-05540   \n",
       "1841  a0ROZ00000DGeA52AL                 Upadacitinib         A-05543   \n",
       "1919  a0ROZ00000DKizt2AD                pembrolizumab         A-05472   \n",
       "1126  a0ROZ00000DoZ9Z2AV                   Emicizumab         A-05466   \n",
       "\n",
       "     Brand_Name__c             Chemical_Name__c  \\\n",
       "688      Risperdal          Risperidone tablets   \n",
       "584      Neurontin                   Gabapentin   \n",
       "982     Genotropin  Somatropin - Growth Hormone   \n",
       "593      Betaferon       Interferon beta-1-beta   \n",
       "1407      Arimidex                  Anastrozole   \n",
       "...            ...                          ...   \n",
       "1282       ADEMPAS                    Riociguat   \n",
       "1770        Nucala                  Mepolizumab   \n",
       "1841        Rinvoq                 Upadacitinib   \n",
       "1919      KEYTRUDA                pembrolizumab   \n",
       "1126      Hemlibra                   Emicizumab   \n",
       "\n",
       "                                  Applicants__c  \\\n",
       "688                                     Janssen   \n",
       "584                                 Parke Davis   \n",
       "982                                   Clinician   \n",
       "593                                       Bayer   \n",
       "1407                                AstraZeneca   \n",
       "...                                         ...   \n",
       "1282                                  Clinician   \n",
       "1770                 GLAXOSMITHKLINE NZ LIMITED   \n",
       "1841                             ABBVIE LIMITED   \n",
       "1919  MERCK SHARP & DOHME (NEW ZEALAND) LIMITED   \n",
       "1126                                  Clinician   \n",
       "\n",
       "                               Funding_requested_for__c  \\\n",
       "688                                       Schizophrenia   \n",
       "584   Partial seizures in patients who have not achi...   \n",
       "982   Adult  and adolescent  patients with growth ho...   \n",
       "593              Relapsing remitting multiple sclerosis   \n",
       "1407     Third line treatment of advanced breast cancer   \n",
       "...                                                 ...   \n",
       "1282  Chronic Thromboembolic Pulmonary Hypertension ...   \n",
       "1770  Inadequately controlled chronic obstructive pu...   \n",
       "1841  Giant cell ateritis (GCA), glucocorticoid tape...   \n",
       "1919  Squamous Cell Carcinoma of the Head and Neck, ...   \n",
       "1126  Haemophilia A, moderate severity, severe bleed...   \n",
       "\n",
       "                     Stage__c                         Pharmaceutical__c  \\\n",
       "688                  Decision           Risperidone tablets (Risperdal)   \n",
       "584                  Decision                    Gabapentin (Neurontin)   \n",
       "982                  Decision  Somatropin - Growth Hormone (Genotropin)   \n",
       "593                  Decision        Interferon beta-1-beta (Betaferon)   \n",
       "1407                 Decision                    Anastrozole (Arimidex)   \n",
       "...                       ...                                       ...   \n",
       "1282  Seeking Clinical Advice                       Riociguat (ADEMPAS)   \n",
       "1770  Seeking Clinical Advice                      Mepolizumab (Nucala)   \n",
       "1841  Seeking Clinical Advice                     Upadacitinib (Rinvoq)   \n",
       "1919  Seeking Clinical Advice                  pembrolizumab (KEYTRUDA)   \n",
       "1126  Seeking Clinical Advice                     Emicizumab (Hemlibra)   \n",
       "\n",
       "                                       Community_URL__c  \\\n",
       "688   https://connect.pharmac.govt.nz/apptracker/s/a...   \n",
       "584   https://connect.pharmac.govt.nz/apptracker/s/a...   \n",
       "982   https://connect.pharmac.govt.nz/apptracker/s/a...   \n",
       "593   https://connect.pharmac.govt.nz/apptracker/s/a...   \n",
       "1407  https://connect.pharmac.govt.nz/apptracker/s/a...   \n",
       "...                                                 ...   \n",
       "1282  https://connect.pharmac.govt.nz/apptracker/s/a...   \n",
       "1770  https://connect.pharmac.govt.nz/apptracker/s/a...   \n",
       "1841  https://connect.pharmac.govt.nz/apptracker/s/a...   \n",
       "1919  https://connect.pharmac.govt.nz/apptracker/s/a...   \n",
       "1126  https://connect.pharmac.govt.nz/apptracker/s/a...   \n",
       "\n",
       "                                   Therapeutic_group__c  \\\n",
       "688                                      Nervous System   \n",
       "584                                      Nervous System   \n",
       "982   Hormone Preparations - Systemic Excluding Cont...   \n",
       "593                                      Nervous System   \n",
       "1407             Oncology Agents and Immunosuppressants   \n",
       "...                                                 ...   \n",
       "1282                                                NaN   \n",
       "1770                   Respiratory System and Allergies   \n",
       "1841                             Musculoskeletal System   \n",
       "1919                                                NaN   \n",
       "1126                                                NaN   \n",
       "\n",
       "     Application Received date Last Update date  \\\n",
       "688                 1994-04-01       1995-10-01   \n",
       "584                 1994-08-01       2001-03-01   \n",
       "982                 1995-09-01       2005-09-01   \n",
       "593                 1996-01-01       1999-07-01   \n",
       "1407                1997-02-01       1998-12-01   \n",
       "...                        ...              ...   \n",
       "1282                2025-10-28       2026-02-02   \n",
       "1770                2025-10-31       2026-01-09   \n",
       "1841                2025-10-31       2026-01-05   \n",
       "1919                2025-12-19       2026-01-09   \n",
       "1126                2026-01-14       2026-02-03   \n",
       "\n",
       "      Days elapsed between application and last update  \\\n",
       "688                                                548   \n",
       "584                                               2404   \n",
       "982                                               3653   \n",
       "593                                               1277   \n",
       "1407                                               668   \n",
       "...                                                ...   \n",
       "1282                                                97   \n",
       "1770                                                70   \n",
       "1841                                                66   \n",
       "1919                                                21   \n",
       "1126                                                20   \n",
       "\n",
       "           Application Received dates  \\\n",
       "688   1994-04-01:Application received   \n",
       "584   1994-08-01:Application received   \n",
       "982   1995-09-01:Application received   \n",
       "593   1996-01-01:Application received   \n",
       "1407  1997-02-01:Application received   \n",
       "...                               ...   \n",
       "1282  2025-10-28:Application received   \n",
       "1770  2025-10-31:Application received   \n",
       "1841  2025-10-31:Application received   \n",
       "1919  2025-12-19:Application received   \n",
       "1126  2026-01-14:Application received   \n",
       "\n",
       "                          Seeking Clinical Advice dates  \\\n",
       "688   1994-04-01:Clinical advice required\\r\\n1994-06...   \n",
       "584   1995-02-01:Clinical advice required\\r\\n1995-03...   \n",
       "982   1995-09-01:Clinical advice required\\r\\n1995-11...   \n",
       "593   1996-01-01:Clinical advice required\\r\\n1996-03...   \n",
       "1407  1997-02-01:Clinical advice required\\r\\n1997-05...   \n",
       "...                                                 ...   \n",
       "1282                2026-02-02:Clinical advice required   \n",
       "1770                2026-01-09:Clinical advice required   \n",
       "1841                2026-01-05:Clinical advice required   \n",
       "1919                2026-01-09:Clinical advice required   \n",
       "1126                2026-02-03:Clinical advice required   \n",
       "\n",
       "                                 Under Assessment dates  \\\n",
       "688   1994-12-01:Working to compare options\\r\\n1995-...   \n",
       "584               1995-03-01:Working to compare options   \n",
       "982               1996-11-01:Working to compare options   \n",
       "593                                                 NaN   \n",
       "1407              1997-05-01:Working to compare options   \n",
       "...                                                 ...   \n",
       "1282                                                NaN   \n",
       "1770                                                NaN   \n",
       "1841                                                NaN   \n",
       "1919                                                NaN   \n",
       "1126                                                NaN   \n",
       "\n",
       "                                 Options Compared dates  \\\n",
       "688   1994-09-01:The relative ranking of the pharmac...   \n",
       "584   1995-05-01:The relative ranking of the pharmac...   \n",
       "982   1995-11-01:The relative ranking of the pharmac...   \n",
       "593   1999-05-01:The relative ranking of the pharmac...   \n",
       "1407  1998-10-01:The relative ranking of the pharmac...   \n",
       "...                                                 ...   \n",
       "1282                                                NaN   \n",
       "1770                                                NaN   \n",
       "1841                                                NaN   \n",
       "1919                                                NaN   \n",
       "1126                                                NaN   \n",
       "\n",
       "                               Under Consultation dates  \\\n",
       "688                                                 NaN   \n",
       "584   2001-01-01:Public consultation for this applic...   \n",
       "982   2009-10-01:Public consultation for this applic...   \n",
       "593   1999-05-01:Public consultation for this applic...   \n",
       "1407  1998-10-01:Public consultation for this applic...   \n",
       "...                                                 ...   \n",
       "1282                                                NaN   \n",
       "1770                                                NaN   \n",
       "1841                                                NaN   \n",
       "1919                                                NaN   \n",
       "1126                                                NaN   \n",
       "\n",
       "     Reviewing Consultation Feedback dates  \\\n",
       "688                                    NaN   \n",
       "584                                    NaN   \n",
       "982                                    NaN   \n",
       "593                                    NaN   \n",
       "1407                                   NaN   \n",
       "...                                    ...   \n",
       "1282                                   NaN   \n",
       "1770                                   NaN   \n",
       "1841                                   NaN   \n",
       "1919                                   NaN   \n",
       "1126                                   NaN   \n",
       "\n",
       "                                         Decision dates  \n",
       "688   1995-10-01:The funding application has been Ap...  \n",
       "584   2001-03-01:The funding application has been Ap...  \n",
       "982   2005-09-01:The funding application has been Ap...  \n",
       "593   1999-07-01:The funding application has been Ap...  \n",
       "1407  1998-12-01:The funding application has been Ap...  \n",
       "...                                                 ...  \n",
       "1282                                                NaN  \n",
       "1770                                                NaN  \n",
       "1841                                                NaN  \n",
       "1919                                                NaN  \n",
       "1126                                                NaN  \n",
       "\n",
       "[2015 rows x 21 columns]"
      ]
     },
     "execution_count": 6,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df[cols]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 7,
   "id": "4df5a02b",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "<Axes: xlabel='Stage__c'>"
      ]
     },
     "execution_count": 7,
     "metadata": {},
     "output_type": "execute_result"
    },
    {
     "data": {
      "image/png": "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",
      "text/plain": [
       "<Figure size 640x480 with 1 Axes>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "df.Stage__c.value_counts().plot.bar()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 8,
   "id": "926ada7c",
   "metadata": {},
   "outputs": [],
   "source": [
    "df[cols].to_excel(\"Pharmac applications.xlsx\", index=False)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 9,
   "id": "3b7e0fc2",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "count    2015.000000\n",
       "mean     1390.057072\n",
       "std      1372.478161\n",
       "min       -94.000000\n",
       "25%       485.000000\n",
       "50%       866.000000\n",
       "75%      1844.500000\n",
       "max      9922.000000\n",
       "Name: Days elapsed between application and last update, dtype: float64"
      ]
     },
     "execution_count": 9,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df[\"Days elapsed between application and last update\"].describe()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 10,
   "id": "c6e0cba0",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "<Axes: title={'center': 'Number of applications last updated per month'}, xlabel='Last Update date'>"
      ]
     },
     "execution_count": 10,
     "metadata": {},
     "output_type": "execute_result"
    },
    {
     "data": {
      "image/png": "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",
      "text/plain": [
       "<Figure size 1200x600 with 1 Axes>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "df[\"Last Update date\"].groupby(df[\"Last Update date\"].dt.to_period(\"M\")).count().plot(figsize=(12, 6), title=\"Number of applications last updated per month\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 11,
   "id": "c0de9b54",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "<Axes: title={'center': 'Number of applications received per month'}, xlabel='Application Received date'>"
      ]
     },
     "execution_count": 11,
     "metadata": {},
     "output_type": "execute_result"
    },
    {
     "data": {
      "image/png": "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",
      "text/plain": [
       "<Figure size 1200x600 with 1 Axes>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "df[\"Application Received date\"].groupby(df[\"Application Received date\"].dt.to_period(\"M\")).count().plot(figsize=(12, 6), title=\"Number of applications received per month\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 12,
   "id": "f7492dcb",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "Application Received date\n",
       "2011-01-01    276\n",
       "2012-05-01     27\n",
       "2014-08-01     21\n",
       "2013-11-01     20\n",
       "2010-03-01     18\n",
       "             ... \n",
       "2016-11-08      1\n",
       "2016-11-07      1\n",
       "2016-11-01      1\n",
       "2016-10-18      1\n",
       "2026-01-14      1\n",
       "Name: count, Length: 790, dtype: int64"
      ]
     },
     "execution_count": 12,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df[\"Application Received date\"].value_counts()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 13,
   "id": "0f476c53",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "Decision dates\n",
       "The funding application has been approved.        871\n",
       "The funding application has been declined.        595\n",
       "The funding application has been .                 11\n",
       "The funding application has been out of scope.      3\n",
       "The funding application is closed.                  1\n",
       "Name: count, dtype: int64"
      ]
     },
     "execution_count": 13,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df[\"Decision dates\"].dropna().str.replace(\"Declined\", \"declined\").str.replace(\"Approved\", \"approved\").str.split(\"\\r\\n\").apply(lambda x: x[-1].split(\":\")[1]).value_counts()"
   ]
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "Python 3",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.12.3"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 5
}
